Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma

Annals of Oncology

Volumn 19, Issue 2, 2008, Pages 242-246

  Song, E K ^a,b   Kim, S Y ^a   Kim, T M ^a   Lee, K W ^a   Yun, T ^a   Na, I I ^a   Shin, H ^a   Lee, S H ^a   Kim, D W ^a   Khwarg, S I ^a   Heo, D S ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

Chemotherapy; MALT lymphoma; Ocular adnexal lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CATARACT; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EYE CANCER; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OCULAR ADNEXAL EXTRANODAL MARGINAL ZONE B CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; XEROPHTHALMIA;

EID: 38849176046     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm457     Document Type: Article

References (26)

1. Nutting CM, Jenkins CD, Norton AJ et al. Primary orbital lymphome. Hematol J 2002; 3: 14-16.
2. Volpe NJ, Gausas RE. Optic nerve and orbital tumors. Neurosurg Clin N Am 1999; 10: 699-715, ix-x.
3. Lee SW, Suh CO, Kim GE et al. Role of radiotherapy for primary orbital lymphoma. Am J Clin Oncol 2002; 25: 261-265.
4. Decaudin D, de Cremoux P, Vincent-Salomon A et al. Ocular adnexal lymphoma: A review of clinicopathologic features and treatment, options. Blood 2006; 108: 1451-1460.
5. Lee JL, Kim MK, Lee KH et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular-adnexa. Ann Hematol 2005; 84: 13-18.
6. Ben Simon GJ, Cheung N, McKelvie P et al. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 2006; 113: 1209-1213.
7. Cheson BD, Homing SJ, Coiffier B at al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
9. Valvassori GE, Sabnis SS, Mafee RF et al. Imaging of orbital lymphoproliferative disorders. Radiol Clin North Am 1999; 37: 135-150, x-xi.
10. Meunier J, Lumbroso-Le Rouic L, Vincent-Salomon A et al. Ophthalmologic and intraocular non-Hodgkin's lymphoma: A large single centre study of initial characteristics, natural history, and prognostic factors. Hematol Oncol 2004; 22: 143-158.
11. Ferreri AJ, Viale E, Guidoboni M et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol 2006; 17: 769-772.
12. Uno T, Isobe K, Shikama N et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: A multiInstitutional, retrospective review of 50 patients. Cancer 2003; 98: 865-871.
13. Rosado MF, Byrne GE Jr, Ding F et al. Ocular adnexal lymphoma: A clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood 2006; 107: 467-472.
14. Bhatia S, Paulino AC, Buatti JM et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 2002; 54: 818-823.
15. Martinet S, Ozsahin M, Belkacemi Y et al. Outcome and prognostic factors in orbital lymphoma: A rare cancer network study an 90 consecutive patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55: 892-898.
16. Ferreri AJ, Ponzoni M, Guidoboni M et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: A multicenter prospective trial. J Nal Cancer Inst 2006; 98: 1375-1382.
17. Jenkins C, Rose GE, Bunce C et al. Clinical features associated with survival of patents with lymphoma of the ocular adnexa. Eye 2003; 17: 809-820.
18. Esik O, Ikeda H, Mukai K, Kaneko A. A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin's lymphomas. Radiother Oncol 1996; 38: 13-18.
19. Ferreri AJ, Ponzoni M, Guldoboni M et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005; 23: 5067-5073.
20. Grunberger B, Hauff W, Lukas J et al. 'Blind antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa. Ann Oncol 2006; 17: 484-487.
21. Tanimoto K, Kaneko A, Suzuki S et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 2006; 17: 135-140.
22. Ferreri AJ, Ponzoni M, Martinelli G et al. Rituximab in patients with mucosal-associated lymphoid fissue-type lymphoma of the ocular adnexa. Haematologica 2005; 90: 1578-1579.
23. Rigacci L, Nassi L, Puccioni M et al. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. Ann Hematol 2007; 86: 565-568.
24. Travis LB, Curtis RE, Glimelius B et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932-1937.
25. Travis LB, Curtis RE, Stovall M et al. Risk of leukemia following treatment for non-Hodgikin's lymphoma. J Natl Cancer Inst 1994; 86: 1450-1457.
26. Lenz G, Dreyling M, Schiegnitz E et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926-4933.